Abstract: We present a Mathematics of Arrays (MoA) and ψ-calculus derivation of the memory-optimal operational normal form for ELLPACK sparse matrix-vector multiplication (SpMV) on GPUs. Under the ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The Milwaukee Journal Sentinel wants to know how the price of groceries is affecting your household. As the holiday shopping season gets into full swing, many shoppers are coping with buying gifts on ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

The Journal Sentinel's John Steppe discusses Wisconsin's 74-63 loss to TCU in the Rady Children's Invitational championship game. Jorge Polanco reportedly agrees to 2-year, $40 million deal with Mets ...

Journal Sentinel preps reporter Zac Bellman previews the matchups of seven area football teams still alive in the WIAA playoffs entering Nov. 14. 2025 Fantasy Football Rankings: Justin Boone's top ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Halloween is more than just getting scared. It's a fun time of the year for people of all ages. Candy. Costume parties. Spooky decorations. And the Journal Sentinel this year wants to feature your ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...